Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study.

Gountas I, Sypsa V, Papatheodoridis G, Paraskevis D, Kalamitsis G, Anagnostou O, Antaraki A, Fotiou A, Hatzakis A.

J Viral Hepat. 2019 Nov;26(11):1311-1317. doi: 10.1111/jvh.13178. Epub 2019 Aug 18.

PMID:
31322302
2.

Aiming towards hepatitis C virus elimination in Greece.

Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, Dalekos GN.

Ann Gastroenterol. 2019 Jul-Aug;32(4):321-329. doi: 10.20524/aog.2019.0375. Epub 2019 Apr 5.

3.

Why do HIV outbreaks re-emerge among people who inject drugs?

Sypsa V.

Lancet HIV. 2019 May;6(5):e274-e275. doi: 10.1016/S2352-3018(19)30079-7. Epub 2019 Apr 10. No abstract available.

PMID:
30981673
4.

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.

Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A.

World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.

5.

The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.

Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J.

J Virus Erad. 2019 Jan 1;5(1):60-66.

6.

HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.

Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A.

PLoS One. 2018 Aug 16;13(8):e0202109. doi: 10.1371/journal.pone.0202109. eCollection 2018.

7.

Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project): Phylogenetics Identify HIV-1-Infected Individuals With Social Links.

Kostaki EG, Nikolopoulos GK, Pavlitina E, Williams L, Magiorkinis G, Schneider J, Skaathun B, Morgan E, Psichogiou M, Daikos GL, Sypsa V, Smyrnov P, Korobchuk A, Malliori M, Hatzakis A, Friedman SR, Paraskevis D.

J Infect Dis. 2018 Jul 24;218(5):707-715. doi: 10.1093/infdis/jiy239.

8.

Molecular investigation of HIV-1 cross-group transmissions during an outbreak among people who inject drugs (2011-2014) in Athens, Greece.

Paraskevis D, Nikolopoulos GK, Sypsa V, Psichogiou M, Pantavou K, Kostaki E, Karamitros T, Paraskeva D, Schneider J, Malliori M, Friedman SR, Des Jarlais DC, Daikos GL, Hatzakis A.

Infect Genet Evol. 2018 Aug;62:11-16. doi: 10.1016/j.meegid.2018.04.010. Epub 2018 Apr 10.

9.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P.

J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8.

PMID:
29427727
10.

Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece.

Giannou F, Nikolopoulos GK, Pantavou K, Benetou V, Kantzanou M, Sypsa V, Williams LD, Friedman SR, Hatzakis A.

Curr HIV Res. 2017;15(6):386-395. doi: 10.2174/1570162X15666171122165636.

11.

Molecular Tracing of the Geographical Origin of Human Immunodeficiency Virus Type 1 Infection and Patterns of Epidemic Spread Among Migrants Who Inject Drugs in Athens.

Paraskevis D, Kostaki E, Nikolopoulos GK, Sypsa V, Psichogiou M, Del Amo J, Hodges-Mameletzis I, Paraskeva D, Skoutelis A, Malliori M, Williams L, Friedman SR, Daikos GL, Hatzakis A.

Clin Infect Dis. 2017 Nov 29;65(12):2078-2084. doi: 10.1093/cid/cix717.

12.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P.

Hepatology. 2017 Nov;66(5):1444-1453. doi: 10.1002/hep.29320. Epub 2017 Oct 11.

PMID:
28622419
13.

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, Dolan K, Galvin B, Vickerman P, Lazarus JV, Mravčík V, Kretzschmar M, Sypsa V, Sarasa-Renedo A, Uusküla A, Paraskevis D, Mendão L, Rossi D, van Gelder N, Mitcheson L, Paoli L, Gomez CD, Milhet M, Dascalu N, Knight J, Hay G, Kalamara E, Simon R; EUBEST working group, Comiskey C, Rossi C, Griffiths P.

Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6.

14.

Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.

Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Micha K, Malliori M, Pharris A, Wiessing L, Donoghoe M, Friedman S, Jarlais DD, Daikos G, Hatzakis A.

J Infect Dis. 2017 May 15;215(10):1496-1505. doi: 10.1093/infdis/jix100.

15.

Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A.

Addiction. 2017 Jul;112(7):1290-1299. doi: 10.1111/add.13764. Epub 2017 Feb 17.

16.

A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP).

Nikolopoulos GK, Pavlitina E, Muth SQ, Schneider J, Psichogiou M, Williams LD, Paraskevis D, Sypsa V, Magiorkinis G, Smyrnov P, Korobchuk A, Vasylyeva TI, Skaathun B, Malliori M, Kafetzopoulos E, Hatzakis A, Friedman SR.

Sci Rep. 2016 Dec 5;6:38100. doi: 10.1038/srep38100.

17.

Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece.

Nikolopoulos GK, Katsoulidou A, Kantzanou M, Rokka C, Tsiara C, Sypsa V, Paraskevis D, Psichogiou M, Friedman S, Hatzakis A.

Epidemiol Infect. 2017 Jan;145(2):401-412. Epub 2016 Oct 26.

18.

Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.

Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A.

J Gastroenterol Hepatol. 2017 Feb;32(2):466-472. doi: 10.1111/jgh.13485.

PMID:
27403912
19.

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P.

J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8.

PMID:
26678008
20.

Enhanced HIV-1 surveillance using molecular epidemiology to study and monitor HIV-1 outbreaks among intravenous drug users (IDUs) in Athens and Bucharest.

Paraskevis D, Paraschiv S, Sypsa V, Nikolopoulos G, Tsiara C, Magiorkinis G, Psichogiou M, Flampouris A, Mardarescu M, Niculescu I, Batan I, Malliori M, Otelea D, Hatzakis A.

Infect Genet Evol. 2015 Oct;35:109-21. doi: 10.1016/j.meegid.2015.08.004. Epub 2015 Aug 4.

PMID:
26247720
21.

Network Characteristics of People Who Inject Drugs Within a New HIV Epidemic Following Austerity in Athens, Greece.

Tsang MA, Schneider JA, Sypsa V, Schumm P, Nikolopoulos GK, Paraskevis D, Friedman SR, Malliori M, Hatzakis A.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):499-508. doi: 10.1097/QAI.0000000000000665.

22.

Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme.

Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC.

Addiction. 2015 Sep;110(9):1453-67. doi: 10.1111/add.12999. Epub 2015 Jul 14.

23.

The interferon receptor-1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection.

Karamitros T, Papatheodoridis G, Dimopoulou E, Papageorgiou MV, Paraskevis D, Magiorkinis G, Sypsa V, Hatzakis A.

Liver Int. 2015 Dec;35(12):2506-13. doi: 10.1111/liv.12859. Epub 2015 May 17.

PMID:
25939635
24.

National income inequality and declining GDP growth rates are associated with increases in HIV diagnoses among people who inject drugs in Europe: a panel data analysis.

Nikolopoulos GK, Fotiou A, Kanavou E, Richardson C, Detsis M, Pharris A, Suk JE, Semenza JC, Costa-Storti C, Paraskevis D, Sypsa V, Malliori MM, Friedman SR, Hatzakis A.

PLoS One. 2015 Apr 15;10(4):e0122367. doi: 10.1371/journal.pone.0122367. eCollection 2015.

25.

A case-control study of MC1R variants in Greek patients with basal cell carcinoma: increased risk independently of pigmentary characteristics.

Dessinioti C, Sypsa V, Kypreou K, Dimisianos G, Kodela E, Nikolaou V, Antoniou C, Stratigos AJ.

Exp Dermatol. 2015 Jun;24(6):476-8. doi: 10.1111/exd.12703. Epub 2015 Apr 16.

PMID:
25809071
26.

Big Events in Greece and HIV Infection Among People Who Inject Drugs.

Nikolopoulos GK, Sypsa V, Bonovas S, Paraskevis D, Malliori-Minerva M, Hatzakis A, Friedman SR.

Subst Use Misuse. 2015;50(7):825-38. doi: 10.3109/10826084.2015.978659. Epub 2015 Feb 27.

27.

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.

J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.

PMID:
25560841
28.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.

J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.

PMID:
25560840
29.

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower E.

J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.

PMID:
25560839
30.

Histological features of chronic hepatitis C in haemodialysis patients.

Sakellariou S, Boletis JN, Sypsa V, Psichogiou M, Tiniakos D, Delladetsima I.

Liver Int. 2014 Jul;34(6):e56-61. doi: 10.1111/liv.12413. Epub 2013 Dec 17.

PMID:
25234282
31.

Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey.

Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A.

J Viral Hepat. 2015 Apr;22(4):409-15. doi: 10.1111/jvh.12314. Epub 2014 Sep 11.

PMID:
25209157
32.

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P.

J Hepatol. 2015 Feb;62(2):363-70. doi: 10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6.

PMID:
25195548
33.

Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece.

Sypsa V, Paraskevis D, Malliori M, Nikolopoulos GK, Panopoulos A, Kantzanou M, Katsoulidou A, Psichogiou M, Fotiou A, Pharris A, Van De Laar M, Wiessing L, Jarlais DD, Friedman SR, Hatzakis A.

Am J Public Health. 2015 Jan;105(1):196-204.

34.

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.

Panagopoulos P, Paraskevis D, Katsarolis I, Sypsa V, Detsika M, Protopapas K, Antoniadou A, Papadopoulos A, Petrikkos G, Hatzakis A.

Int J STD AIDS. 2014 Oct;25(12):860-5. doi: 10.1177/0956462414523259. Epub 2014 Feb 10.

PMID:
24516079
35.

Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.

Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A.

Antimicrob Agents Chemother. 2014;58(4):2322-8. doi: 10.1128/AAC.02166-13. Epub 2014 Feb 10.

36.

Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study.

Paraskevis D, Nikolopoulos G, Fotiou A, Tsiara C, Paraskeva D, Sypsa V, Lazanas M, Gargalianos P, Psichogiou M, Skoutelis A, Wiessing L, Friedman SR, Jarlais DC, Terzidou M, Kremastinou J, Malliori M, Hatzakis A.

PLoS One. 2013 Nov 12;8(11):e78941. doi: 10.1371/journal.pone.0078941. eCollection 2013.

37.

Socially-integrated transdisciplinary HIV prevention.

Friedman SR, Downing MJ Jr, Smyrnov P, Nikolopoulos G, Schneider JA, Livak B, Magiorkinis G, Slobodianyk L, Vasylyeva TI, Paraskevis D, Psichogiou M, Sypsa V, Malliori MM, Hatzakis A.

AIDS Behav. 2014 Oct;18(10):1821-34. doi: 10.1007/s10461-013-0643-5.

38.

Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D.

Katsoulidou A, Manesis E, Rokka C, Issaris C, Pagoni A, Sypsa V, Hatzakis A.

J Viral Hepat. 2013 Apr;20(4):256-62. doi: 10.1111/jvh.12000. Epub 2012 Sep 13.

PMID:
23490370
39.

Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics.

Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, Fraser C, Pybus OG, Hatzakis A.

PLoS Comput Biol. 2013;9(1):e1002876. doi: 10.1371/journal.pcbi.1002876. Epub 2013 Jan 31.

40.

Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression.

Delladetsima I, Psichogiou M, Sypsa V, Sakellariou S, Hatzakis A, N Boletis J.

Clin Transplant. 2013 Jan-Feb;27(1):72-9. doi: 10.1111/ctr.12012. Epub 2012 Sep 19.

PMID:
22994949
41.

Transmission dynamics of carbapenemase-producing Klebsiella pneumoniae and anticipated impact of infection control strategies in a surgical unit.

Sypsa V, Psichogiou M, Bouzala GA, Hadjihannas L, Hatzakis A, Daikos GL.

PLoS One. 2012;7(7):e41068. doi: 10.1371/journal.pone.0041068. Epub 2012 Jul 31.

42.

Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.

Karamitros T, Kakkanas A, Katsoulidou A, Sypsa V, Dalagiorgou G, Mavromara P, Hatzakis A.

J Viral Hepat. 2012 Mar;19(3):182-8. doi: 10.1111/j.1365-2893.2011.01502.x. Epub 2011 Oct 4.

PMID:
22329372
43.

Evaluation of self-assessed melanoma growth rate in a Mediterranean patient population.

Nikolaou VA, Sypsa V, Gogas H, Polydorou D, Hasapi V, Gagari E, Stratigos A.

Melanoma Res. 2011 Dec;21(6):560-2. doi: 10.1097/CMR.0b013e32834d3db9. No abstract available.

PMID:
22051509
44.

Estimating the disease burden of 2009 pandemic influenza A(H1N1) from surveillance and household surveys in Greece.

Sypsa V, Bonovas S, Tsiodras S, Baka A, Efstathiou P, Malliori M, Panagiotopoulos T, Nikolakopoulos I, Hatzakis A.

PLoS One. 2011;6(6):e20593. doi: 10.1371/journal.pone.0020593. Epub 2011 Jun 9.

45.

Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece.

Dessinioti C, Tzannis K, Sypsa V, Nikolaou V, Kypreou K, Antoniou C, Katsambas A, Stratigos AJ.

Exp Dermatol. 2011 Aug;20(8):622-6. doi: 10.1111/j.1600-0625.2011.01275.x. Epub 2011 Apr 27.

PMID:
21521370
46.

The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea.

Stamboulidis K, Chatzaki D, Poulakou G, Ioannidou S, Lebessi E, Katsarolis I, Sypsa V, Tsakanikos M, Kafetzis D, Tsolia MN.

Pediatr Infect Dis J. 2011 Jul;30(7):551-5. doi: 10.1097/INF.0b013e31821038d9.

PMID:
21297521
47.

Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece.

Katsoulidou A, Rokka C, Issaris C, Haida C, Tzannis K, Sypsa V, Detsika M, Paraskevis D, Hatzakis A.

Virol J. 2011 Jan 11;8:10. doi: 10.1186/1743-422X-8-10.

48.

HIV/HBV co-infection and rate of antiretroviral treatment change after highly active antiretroviral treatment initiation in a cohort of HIV-infected patients in Greece.

Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, Kalapothaki V, Hatzakis A.

Int J STD AIDS. 2010 Oct;21(10):702-7. doi: 10.1258/ijsa.2010.010112.

PMID:
21139149
49.

Hepatic progenitor cells in chronic hepatitis C: a phenomenon of older age and advanced liver disease.

Delladetsima J, Alexandrou P, Giaslakiotis K, Psichogiou M, Hatzis G, Sypsa V, Tiniakos D.

Virchows Arch. 2010 Oct;457(4):457-66. doi: 10.1007/s00428-010-0957-x. Epub 2010 Aug 19.

PMID:
20721577
50.

Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA.

Paraskevis D, Beloukas A, Haida C, Katsoulidou A, Moschidis Z, Hatzitheodorou H, Varaklioti A, Sypsa V, Hatzakis A.

Virol J. 2010 Mar 12;7:57. doi: 10.1186/1743-422X-7-57.

Supplemental Content

Support Center